These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10894285)

  • 21. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
    Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
    Gianotti N; Tambussi G; Boeri E; Lazzarin A
    J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
    Maguire M; Gartland M; Moore S; Hill A; Tisdale M; Harrigan R; Kleim JP
    AIDS; 2000 Jun; 14(9):1195-201. PubMed ID: 10894284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
    Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
    AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.
    Ray N; Li T; Lin Z; Protack T; van Ham PM; Hwang C; Krystal M; Nijhuis M; Lataillade M; Dicker I
    J Acquir Immune Defic Syndr; 2017 May; 75(1):52-60. PubMed ID: 28234686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
    Kaltenbach RF; Trainor G; Getman D; Harris G; Garber S; Cordova B; Bacheler L; Jeffrey S; Logue K; Cawood P; Klabe R; Diamond S; Davies M; Saye J; Jona J; Erickson-Viitanen S
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3021-8. PubMed ID: 11600351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
    Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
    J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.
    Agwale SM; Zeh C; Paxinos E; Odama L; Pienazek D; Wambebe C; Kalish ML; Ziermann R
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):22-6. PubMed ID: 16438641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
    Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
    J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
    Condra JH; Holder DJ; Schleif WA; Blahy OM; Danovich RM; Gabryelski LJ; Graham DJ; Laird D; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M; Yang T; Chodakewitz JA; Deutsch PJ; Leavitt RY; Massari FE; Mellors JW; Squires KE; Steigbigel RT; Teppler H; Emini EA
    J Virol; 1996 Dec; 70(12):8270-6. PubMed ID: 8970946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.